- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05494853
Novel Biomarker Assay for Biomarker Assay for HCC Detection (GTH_HCC)
Novel Biomarker Assay for HCC Detection and Monitoring Piedmont Transplant Institute and Genetron Health, Inc.
Study Overview
Status
Conditions
Detailed Description
HCC is a leading cause of cancer-related deaths in the US. Early detection is crucial to improve the outcome of HCC. HCC surveillance is recommended for early detection of HCC in patients with cirrhosis. However, current HCC surveillance tests, such as liver ultrasound and AFP have relatively low accuracy for the detection of early-stage HCC. Genetron Health recently published on novel liquid biopsy biomarker for detection of HCC in China. The biomarker showed excellent performance for the detection of HCC among the at-risk population, most of whom had HBV infection. It is crucial to validate the performance of this novel biomarker in an independent population of patients with different etiology of liver disease outside of China. As this novel biomarker is useful in the detection of small HCC, it may also serve as an excellent biomarker for assessment of treatment response and monitoring of recurrence.
The primary purpose of this study is to assess the performance feasibility of Genetron's novel HCC liquid biopsy biomarkers assay for early detection. Piedmont Transplant Institute will provide a longitudinally collected blood sample from all HCC cases (mixture of early and advanced stage HCC) and cirrhosis control to Genetron Health after obtaining informed consent. Genetron Health will analyze the blood sample and provide data to the PI, for internal review purposes. Should the initial pilot study be successful, the parties will have a discussion to expand the number of cases and control samples and consider conducting a multicenter prospective study.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Moin Ahmad
- Phone Number: 12403506177
- Email: mahmad@genetronhealth.us
Study Contact Backup
- Name: Hai Yan
- Phone Number: 3015080881
- Email: hyan@genetronhealth.us
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with HCC (based on histology or radiology according to AASLD guideline) or liver cirrhosis (based on the clinical history of hepatic encephalopathy, thrombocytopenia, radiologic features of the nodular liver, features of portal hypertension such as ascites, splenomegaly, or MR elastogram or fibroscan showing result consistent with cirrhosis)
- Willing and able to provide informed consent to participate in this study
Exclusion Criteria:
- Unable to provide blood samples
- Age less than 18 years of age
- Patient who have active cancers (excluding HCC) in the past five years, except for nonmelanoma skin cancer
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
HCC
HCC positive
|
Non HCC
HCC negative
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HCC screening positive
Time Frame: 2 years
|
Data will suggest the probability of HCC
|
2 years
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GTH_HCC2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepato-cellular Carcinoma
-
Bristol-Myers SquibbCompletedHepato Cellular Carcinoma (HCC)United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Hong Kong, India, Italy, Japan, Korea, Republic of, Mexico, Poland, Puerto Rico, Russian Federation, South Africa, Spain, Sweden, ... and more
-
University Hospital, Strasbourg, FranceCompletedHepato Cellular CarcinomaFrance
-
Stanford UniversityTerminatedKidney (Renal Cell) CancerUnited States
-
K. Sreekumaran NairNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Institut National de la Santé Et de la Recherche...Completed
-
Deepali KumarCompleted
-
University of California, Los AngelesNIH T32 Human and Molecular Development Training GrantCompletedIntestinal Transplant | Cellular RejectionUnited States
-
The Methodist Hospital Research InstituteUnknownAcute (Cellular) Renal Allograft RejectionUnited States
-
London School of Hygiene and Tropical MedicineCompletedImmunity, Cellular | Hypersensitivity, Delayed TypeMalawi, United Kingdom
-
Royal Marsden NHS Foundation TrustRecruitingGastric Cancer | Colorectal Cancer | Pancreatic Cancer | Oesophageal Cancer | Hepato-Biliary Carcinoma in Situ NosUnited Kingdom